United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - cefazolin sodium (unii: p380m0454z) (cefazolin - unii:ihs69l0y4t) - cefazolin for injection, usp is indicated for the treatment of the following serious infections due to susceptible organisms: respiratory tract infections: due to s. pneumoniae, klebsiella species, h. influenzae, s. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-hemolytic streptococci. injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin for injection, usp is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin for injection, usp in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections: due to e. coli, p. mirabilis, klebsiella species, and some strains of enterobacter and enterococci. skin and skin structure infections: due to s. aureus (penicillin-sensitive and penicillin-resistant), group a beta-hemolytic streptococci, and other strains of

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - cefazolin sodium (unii: p380m0454z) (cefazolin - unii:ihs69l0y4t) - cefazolin for injection, usp is indicated for the treatment of the following serious infections due to susceptible organisms: respiratory tract infections: due to s. pneumoniae, klebsiella species, h. influenzae, s. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-hemolytic streptococci. injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin for injection, usp is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin for injection, usp in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections: due to e. coli, p. mirabilis, klebsiella species, and some strains of enterobacter and enterococci. skin and skin structure infections: due to s. aureus (penicillin-sensitive and penicillin-resistant), group a beta-hemolytic streptococci, and other strains of

Malta - English - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - cefazolin sodium - powder for solution for injection/infusion - cefazolin sodium 1 g - antibacterials for systemic use

United States - English - NLM (National Library of Medicine)

cardinal health - cefazolin sodium (unii: p380m0454z) (cefazolin - unii:ihs69l0y4t) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefazolin for injection, usp and other antibacterial drugs, cefazolin for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefazolin for injection, usp is indicated for the treatment of the following serious infections due to susceptible organisms. respiratory tract infections due to s. pneumoniae , klebsiella species, h. influenzae , s. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-hemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cefazolin sodium, quantity: 2.097 mg - injection, powder for - excipient ingredients: - treatment of the following serious infections due to susceptible organisms: ? respiratory tract infections due to strep. pneumoniae, klebsiella sp., h. influenzae, staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present. ? genitourinary tract infections due to e. coli, p. mirabilis, klebsiella sp. and some strains of enterobacter and enterococci. ? skin and skin structure infections due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci and other strains of streptococci. ? bone and joint infections due to staph. aureus. ? septicaemia due to strep. pneumoniae, staph. aureus (penicillin sensitive and penicillin resistant), p. mirabilis, e. coli and klebsiella sp. ? endocarditis due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. ? appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cefazolin sodium, quantity: 1048 mg (equivalent: cefazolin, qty 1000 mg) - injection, powder for - excipient ingredients: - indications: treatment of the following serious infections due to susceptible organisms: respiratory tract infections due to strep. pneumoniae, klebsiella sp., h. influenzae, staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephazolin is effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephazolin in the subsequent prevention of rheumatic fever are not available at present. genitourinary tract infections due to e. coli, p. mirabilis, and klebsiella sp and some strains of enterobacter and enterococci. skin and skin structure infections due to staph. aureus (penicillin sensitive and penicillin resisant) and group a beta-haemolytic streptococci and other strains of streptococci. bone and joint infections due to staph. aureus. septicaemia due to strep. pneumoniae, staph. aureus (penicillin sensitive and penicillin resistant), e. coli, p. mirabilis, and klebsiella sp. endocarditis due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. appropriate culture and susceptibility studies should be preformed to determine susceptibility of the causative organism to cephazolin.

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - cefazolin sodium (unii: p380m0454z) (cefazolin - unii:ihs69l0y4t) - cefazolin for injection, usp is indicated for the treatment of the following serious infections due to susceptible organisms: respiratory tract infections: due to s. pneumoniae, klebsiella species, h. influenzae, s. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-hemolytic streptococci. injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin for injection, usp is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin for injection, usp in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections: due to e. coli, p. mirabilis, klebsiella species, and some strains of enterobacter and enterococci. skin and skin structure infections: due to s. aureus (penicillin-sensitive and penicillin-resistant), group a beta-hemolytic streptococci, and other strains of streptococci. biliary tract infections: due to e. coli , various strains of streptococci, p. mirabilis , klebsiella species, and s. aureus . bone and joint infections: due to s. aureus . genital infections: (i.e., prostatitis, epididymitis) due to e. coli , p. mirabilis , klebsiella species, and some strains of enterococci. septicemia: due to s. pneumoniae , s. aureus (penicillin-sensitive and penicillin-resistant), p. mirabilis , e. coli , and klebsiella species. endocarditis: due to s. aureus (penicillin-sensitive and penicillin-resistant) and group a beta-hemolytic streptococci. perioperative prophylaxis: the prophylactic administration of cefazolin for injection, usp preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). the perioperative use of cefazolin for injection, usp may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). the prophylactic administration of cefazolin for injection, usp should usually be discontinued within a 24-hour period after the surgical procedure. in surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of cefazolin for injection, usp may be continued for 3 to 5 days following the completion of surgery. if there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see dosage and administration ). to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefazolin for injection, usp and other antibacterial drugs, cefazolin for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefazolin for injection is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.

Namibia - English - Namibia Medicines Regulatory Council

aspen pharmacare - cefazolin sodium - injection - cefazolin sodium injection equiv. to cefazolin 500mg per vial

Namibia - English - Namibia Medicines Regulatory Council

aspen pharmacare - cefazolin sodium injection - injection - cefazolin sodium injection equiv. to cefazolin 1000mg per vial

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - cefazolin sodium 1048mg equivalent to cefazolin 1 g - powder for injection - 1 g - active: cefazolin sodium 1048mg equivalent to cefazolin 1 g